Targeted therapy prolongs life in patients with HER2-positive breast cancer
Friday, December 11, 2009 - 15:07
in Health & Medicine
SAN ANTONIO -- Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium. Link: http://www.dukemednews.org